Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review

202247 citationsJournal Articlegold Open Access

Authors

Josep M. Llibre · Hospital Universitari Germans Trias i Pujol

Pedro Cahn · Fundación Huésped

Janet Lo · Massachusetts General Hospital

Tristan Barber · Royal Free London NHS Foundation Trust

Cristina Mussini · University of Modena and Reggio Emilia

Berend J. van Welzen · University Medical Center Utrecht

Beatríz Hernández

Abstract

Results show that dolutegravir plus lamivudine has a comparable impact on inflammatory and atherogenesis biomarkers vs 3/4DRs, with no consistent pattern of change after switch in virologically suppressed PWH.

Topics & Keywords

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Open Forum Infectious Diseases

Volume 9, Issue 4, pp. ofac068-ofac068

DOI: 10.1093/ofid/ofac068

Field-Weighted Citation Impact: 11.78